Evidence map›Paper›PMID 36083190›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022

Pediatric solid organ transplant recipients demonstrate robust cell-mediated and humoral responses to three doses of mRNA SARS-CoV-2 vaccine.

Julia S Bratic, Hayley A Gans, Sharon F Chen, Niaz Banaei, Erica M Johnston, Katherine Sear, Sarah Samreth, Sruti S Nadimpalli

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Julia S BraticDepartment of Pediatrics, Stanford University, Stanford, California, USA.ORCID 0000-0002-7536-9756
Hayley A GansDivision of Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, California, USA.ORCID 0000-0001-9190-263X
Sharon F ChenDivision of Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, California, USA.ORCID 0000-0002-3705-258X
Niaz BanaeiDepartment of Pathology, Stanford University, Stanford, California, USA.ORCID 0000-0001-8501-3000
Erica M JohnstonStanford Maternal and Child Health Research Institute, Stanford, California, USA.ORCID 0000-0003-4792-1811
Katherine SearDivision of Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, Stanford University, Stanford, California, USA.ORCID 0000-0002-9391-1713
Sarah SamrethDepartment of Pediatrics, Stanford University, Stanford, California, USA.ORCID 0000-0002-5980-1932
Sruti S NadimpalliDivision of Infectious Diseases, Department of Pediatrics, Stanford University, Stanford, California, USA.ORCID 0000-0003-0614-1720
Stanford University · USStanford Health Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric solid organ transplant recipients (pSOTR) often demonstrate suboptimal vaccine responses and are not included in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine efficacy trials. This population has shown variable humoral immunity following SARS-CoV-2 vaccination, and no studies have assessed cell-mediated responses after SARS-CoV-2 vaccination in pSOTR. SARS-CoV-2-specific interferon-gamma release assay (IGRA), immunoglobulin G (IgG), and receptor-binding domain (RBD)-angiotensin-converting enzyme 2 (ACE2) blocking antibody (Ab) were measured in pSOTR aged 5-17 years after 2-3 doses of SARS-CoV-2 mRNA vaccine. In all, 33 subjects were included, with 25 tested after the second dose of mRNA vaccine (V2) and 21 tested after the third dose of mRNA vaccine (V3). Of the 19 subjects who had IgG testing after V3, 100.0% (19/19) had a positive IgG response. Of the 17 subjects who had IGRA testing after V3, 94.1% (16/17) had a positive IGRA response. RBD-ACE2 blocking antibody increased significantly from V2 to V3 (p = .007). Subjects <1 year from transplant demonstrated a significantly larger increase in RBD-ACE2 blocking Ab from V2 to V3 than did those >1 year from transplant (p = .05). SARS-CoV-2 vaccination induces humoral and cell-mediated responses in the majority of pSOTR, with improved quantitative humoral response after three doses.

Indexed as

COVID-19Organ TransplantationAngiotensin-Converting Enzyme 2Antibodies, ViralChildCOVID-19 VaccinesHumansImmunoglobulin GmRNA VaccinesRNA, MessengerSARS-CoV-2Transplant RecipientsVaccinationAngiotensin-Converting Enzyme 2Antibodies, ViralCOVID-19 VaccinesImmunoglobulin GmRNA VaccinesRNA, Messengerclinical research/practiceinfection and infectious agents - viral: SARS-CoV-2/COVID-19infectious diseasevaccine

Identifiers

PMID36083190
PMCPMC9539089
OpenAlexW4295048767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.